- Home
- KOSS vs MAIA Comparison
KOSS vs MAIA Comparison
Compare KOSS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOSS
- MAIA
- Stock Information
- Founded
- KOSS 1953
- MAIA 2018
- Country
- KOSS United States
- MAIA United States
- Employees
- KOSS N/A
- MAIA N/A
- Industry
- KOSS Consumer Electronics/Appliances
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- KOSS Consumer Staples
- MAIA Health Care
- Exchange
- KOSS Nasdaq
- MAIA Nasdaq
- Market Cap
- KOSS 59.3M
- MAIA 46.7M
- IPO Year
- KOSS N/A
- MAIA 2022
- Fundamental
- Price
- KOSS $5.20
- MAIA $1.82
- Analyst Decision
- KOSS
- MAIA
- Analyst Count
- KOSS 0
- MAIA 0
- Target Price
- KOSS N/A
- MAIA N/A
- AVG Volume (30 Days)
- KOSS 90.9K
- MAIA 549.7K
- Earning Date
- KOSS 08-28-2025
- MAIA 08-08-2025
- Dividend Yield
- KOSS N/A
- MAIA N/A
- EPS Growth
- KOSS N/A
- MAIA N/A
- EPS
- KOSS N/A
- MAIA N/A
- Revenue
- KOSS $12,433,361.00
- MAIA N/A
- Revenue This Year
- KOSS N/A
- MAIA N/A
- Revenue Next Year
- KOSS N/A
- MAIA N/A
- P/E Ratio
- KOSS N/A
- MAIA N/A
- Revenue Growth
- KOSS N/A
- MAIA N/A
- 52 Week Low
- KOSS $4.00
- MAIA $1.40
- 52 Week High
- KOSS $18.73
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- KOSS 50.45
- MAIA 53.36
- Support Level
- KOSS $4.83
- MAIA $1.60
- Resistance Level
- KOSS $5.10
- MAIA $2.03
- Average True Range (ATR)
- KOSS 0.30
- MAIA 0.12
- MACD
- KOSS 0.01
- MAIA 0.02
- Stochastic Oscillator
- KOSS 53.57
- MAIA 58.14
About KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.